https://www.selleckchem.com/pr....oducts/deruxtecan.ht
Objective The objective of the study was to establish the compatibility of injectable meropenem with 101 other drugs during Y-site administration. Methods Meropenem (50 mg/mL, 10 mL) was combined with 101 undiluted injectable drugs (10 mL each) at room temperature. Each preparation was performed twice. The first sample underwent a visual evaluation and a particle count test by light obstruction immediately after mixing. These tests were repeated 4 hours after mixing using the second preparation. Incompatibility was defined as precipi